Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2013-09-16

Study Completion Date

2017-12-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

* Androgenetic alopecia (AGA) or common baldness is the most common cause of hair loss in both men and women and is caused by the action of androgens in genetically predisposed individuals.
* This clinical trial was designed to evaluate the efficacy and safety of using a preparation of autologous plasma rich in growth factors (PRGF-Endoret) in the treatment of androgenetic alopecia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia

NCT02999737

Androgenetic Alopecia

UNKNOWN PHASE4

Study to Assess Efficacy of Platelet-Rich Plasma in Androgenetic Alopecia

NCT02393040

Androgenetic Alopecia Alopecia Hair Loss

UNKNOWN NA

Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment

NCT02591355

Androgenetic Alopecia

COMPLETED NA

Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women

NCT03488108

Alopecia

COMPLETED PHASE1/PHASE2

An Exploratory Clinical Study to Assess Safety, Efficacy and In-Use Tolerability of Three Different Hair Growth Products in Patients With Mild to Moderate Androgenic Alopecia (Grade I to III)

NCT06556056

Androgenic Alopecia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Androgenetic Alopecia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PRGF-Endoret

Group Type EXPERIMENTAL

PRGF-Endoret

Intervention Type DEVICE

PRGF-Endoret mesotherapy micro injection.

Saline Solution

Group Type PLACEBO_COMPARATOR

Saline Solution

Intervention Type OTHER

Saline Solution mesotherapy micro injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PRGF-Endoret

PRGF-Endoret mesotherapy micro injection.

Intervention Type DEVICE

Saline Solution

Saline Solution mesotherapy micro injection

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Androgenetic alopecia according to the following scales:
* Men: Hamilton/Norwood Scale: grades II-VI
* Women: Ludwig Scale grades I-II.
* Possibility of follow-up during the study

Exclusion Criteria

* No androgenetic alopecia
* Telogen and anagen effluvium
* Active inflammation or infection in the intervention area
* Presence of active systemic infections.
* Background of cancerous or precancerous lesions.
* Background of connective or rheumatic diseases.
* Suffering from any serious blood disorders.
* To have undergone treatments for alopecia in the previous 6 months.
* Previous hair implants
* Intake of drugs that affect hair loss.
* Be undergoing immunosuppressive therapy and/or anticoagulants.
* Known intolerance to mesotherapy.
* Taking contraceptives containing cyproterone acetate.
* Pregnancy
* In general, any limitations that would prevent the proper application of both treatments and the right monitoring of the efficacy variables.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No